Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®

Inclusion Criteria: * Infants aged 42 to 89 days inclusive on the day of inclusion. * Born at full term of pregnancy (\>37 weeks). * Informed consent form signed by the parent(s) or legally authorized representative. * Able to attend all scheduled visits and to comply with the study procedures. * Parent or legally authorized representative has access to a telephone. * Parent or legally authorized representative able to read and write in English or French. Exclusion Criteria: * Participation in another clinical trial in the 4 weeks preceding the first trial vaccination. * Planned participation in another clinical trial during the present trial period. * Personal or immediate family history of congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy. * Known or suspected systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing the same substances as the trial vaccine(s). * Chronic illness that could interfere with trial conduct or completion. * Received blood or blood-derived products since birth. * Any vaccination preceding the first trial vaccination or planned in the 4 weeks after any trial vaccination (flu vaccine may be given a minimum of 4 weeks prior to the first study vaccination). * Previous vaccination with any acellular pertussis- (DTaP) or whole cell pertussis- (DTwP) based combination vaccines, Haemophilus influenzae type b (Hib)-conjugate, poliovirus, hepatitis B, or pneumococcal conjugate vaccines. * Coagulation disorder contraindicating IM vaccination. * Clinically significant findings on review of systems (determined by investigator or sub-investigator to be sufficient for exclusion). * Developmental delay or neurological disorder. * Any condition which, in the opinion of the investigator, would interfere with the evaluation of the vaccine or pose a health risk to the subject. * Documented Hepatitis B surface Antigen (HBsAg) seropositivity in the child or his/her mother. * History of Hib, hepatitis B, diphtheria, tetanus, pertussis or poliovirus disease.